8-week Safety Profile of Tapentadol Extended Release Tablets Switched from Other Opioids for Well-controlled, Moderate to Severe, Chronic Malignant Tumor-related Pain: Constipation, Nausea, Vomiting and Somnolence

2016 ◽  
Vol 11 (1) ◽  
pp. 116-122
Author(s):  
Keiichiro Imanaka ◽  
Takashi Yoshimura ◽  
Yushin Tominaga ◽  
Hiromi Koga ◽  
Keiichiro Hirose
Keyword(s):  
Malignant Tumor ◽  
Safety Profile ◽  
Extended Release

31.8 REAL-WORLD SAFETY PROFILE OF DELAYED-RELEASE AND EXTENDED-RELEASE METHYLPHENIDATE FOR ADHD IN CHILDREN, ADOLESCENTS, AND ADULTS

2020 ◽  
Vol 59 (10) ◽  
pp. S213
Author(s):  
Ann Catherine Childress ◽  
Victor Otcheretko ◽  
Lewis E. Warrington ◽  
Justin A. Barnes ◽  
Ryan A. Gregg ◽  
...  
Keyword(s):  
Real World ◽  
Safety Profile ◽  
Extended Release ◽  
Delayed Release ◽  
Adolescents And Adults

scholarly journals Ready Conversion of Patients with Well-Controlled, Moderate to Severe, Chronic Malignant Tumor–related Pain on Other Opioids to Tapentadol Extended Release

2014 ◽  
Vol 34 (7) ◽  
pp. 501-511 ◽  
Author(s):  
Keiichiro Imanaka ◽  
Yushin Tominaga ◽  
Mila Etropolski ◽  
Hiroki Ohashi ◽  
Keiichiro Hirose ◽  
...  
Keyword(s):  
Malignant Tumor ◽  
Extended Release

scholarly journals Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial

2014 ◽  
Vol 371 (3) ◽  
pp. 288-290 ◽  
Author(s):  
Todd J. Anderson ◽  
William E. Boden ◽  
Patrice Desvigne-Nickens ◽  
Jerome L. Fleg ◽  
Moti L. Kashyap ◽  
...  
Keyword(s):  
Safety Profile ◽  
Extended Release

Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses

2017 ◽  
Vol 23 (2) ◽  
pp. 111-120 ◽  
Author(s):  
Danielly Chierrito de Oliveira ◽  
Patricia Guerrero de Sousa ◽  
Camila Borges dos Reis ◽  
Fernanda Stumpf Tonin ◽  
Laiza Maria Steimbach ◽  
...  
Keyword(s):  
Safety Profile ◽  
Odds Ratio ◽  
Extended Release ◽  
Controlled Trials ◽  
Mixed Treatment Comparison ◽  
Credibility Interval ◽  
Double Blind ◽  
Treatment Comparison ◽  
Mixed Treatment ◽  
Meta Analyses

Objective: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. Method: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). Results: Ten ( n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]). Conclusion: It was possible to generate evidence about the safety profile of different ADHD drugs.

Bupivacaine Extended-Release Liposome Injection Exhibits a Favorable Cardiac Safety Profile

2012 ◽  
Vol 37 (2) ◽  
pp. 145-151 ◽  
Author(s):  
Sergio D. Bergese ◽  
Erol Onel ◽  
Michael Morren ◽  
Joel Morganroth
Keyword(s):  
Safety Profile ◽  
Extended Release ◽  
Cardiac Safety
Sign in / Sign up

Export Citation Format

Share Document